Publications by authors named "A Nouraldeen"

To identify novel targets for neuropathic pain, 3097 mouse knockout lines were tested in acute and persistent pain behavior assays. One of the lines from this screen, which contained a null allele of the adapter protein-2 associated kinase 1 (AAK1) gene, had a normal response in acute pain assays (hot plate, phase I formalin), but a markedly reduced response to persistent pain in phase II formalin. AAK1 knockout mice also failed to develop tactile allodynia following the Chung procedure of spinal nerve ligation (SNL).

View Article and Find Full Text PDF

Small molecule modulators of GPR88 activity (agonists, antagonists, or modulators) are of interest as potential agents for the treatment of a variety of psychiatric disorders including schizophrenia. A series of phenylglycinol and phenylamine analogs have been prepared and evaluated for their GPR88 agonist activity and pharmacokinetic (PK) properties.

View Article and Find Full Text PDF

The incidence of cognitive disorders such as Alzheimer's disease continues to increase unabated. While cures for such diseases have eluded investigators, progress is being made on alleviating certain symptoms of these diseases. Mouse knockouts of the proline transporter (PROT), a high affinity Na(+)/Cl(-)-dependent transporter, indicated its potential as a novel therapeutic target for cognition improvement.

View Article and Find Full Text PDF

Mammalian sterile 20-like kinase 1 (Mst1) is a MAPK kinase kinase kinase which is involved in a wide range of cellular responses, including apoptosis, lymphocyte adhesion and trafficking. The contribution of Mst1 to Ag-specific immune responses and autoimmunity has not been well defined. In this study, we provide evidence for the essential role of Mst1 in T cell differentiation and autoimmunity, using both genetic and pharmacologic approaches.

View Article and Find Full Text PDF
Article Synopsis
  • Treatments that lower blood glucose and body weight are beneficial for type 2 diabetes patients; LX4211 is a new oral medication that inhibits SGLT1 and SGLT2 to improve glycemic control and promote weight loss.
  • * In preclinical studies, LX4211 effectively blocked glucose transport in various animal models and significantly increased urinary glucose excretion for over 24 hours.
  • * Long-term treatment with LX4211 improved glucose levels and insulin response in diabetic mice, but some weight loss effects were countered by increased food intake in certain models, suggesting a complex relationship between the drug's effects and appetite.
View Article and Find Full Text PDF